Sol Gel Technologies Ltd (SLGL) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sol gel Technologies Ltd   (NASDAQ: SLGL)


Sol Gel Technologies Ltd 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Sol Gel Technologies Ltd 's ROA in the fourth quarter of 2025?
Sol gel Technologies Ltd achieved a return on average assets (ROA) of 15.59 % in its fourth quarter of 2025, this is above SLGL's average return on assets of -34.17%.
Sol Gel Technologies Ltd assets over the 12 months ending in its fourth quarter of 2025 are valued at $35 million

Despite the company's net income deteriorating, Sol Gel Technologies Ltd was able to improve its ROA compared to the third quarter of 2025.

However, within the Healthcare sector 425 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4069.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change -14.79 % -12.71 % -5.74 % -12.71 % -53.27 %
Y / Y Net Income Change - - 487.55 % - -
Net Income (TTM) in million 5 1 1 -9 -9
Return On Assets (TTM) 15.59 % 2.79 % 2.71 % -22.29 % -21.65 %
SLGL's Total Ranking # 4069 # # # # 4449
Total Assets (TTM) in million 39 31 39 31 46
Seq. Total Assets Change 24.76 % -20.36 % 25.57 % -31.7 % 27.81 %
Seq. Net Income Change - - - - -

SLGL's 5 Years Annual ROA >> Back to SLGL Management Effectiveness >> Compare SLGL ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 162
Sector # 426
Overall # 4032

Return On Assets Statistics
High Average Low
4.66 %
-34.17 %
-60.15 %
(Dec 31 2021)   (Dec 31 2023)





Financial Statements
Sol Gel Technologies Ltd 's Assets $ 39 million SLGL's Balance sheet
Sol Gel Technologies Ltd 's Income $ -6 million Quarterly SLGL's Income Statement
SLGL's Income by Division See SLGL's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -14.79 % -53.27 % 11.73 % -40.06 % 44.66 %
Total Assets in million 39 46 98 88 146
Y / Y Net Income Change - - - - -
Net Income in million -6 -11 -27 -15 3
Annual Return On Assets -15.72 % -23.13 % -27.83 % -17.03 % 2.2 %

SLGL's 5 Years Annual ROA >> Back to SLGL Management Effectiveness >> Compare SLGL ROA to its Competitors



More Return On Assets Ratios
SLGL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SLGL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SLGL's Competitors
Subscribers only: Roa for Sol Gel Technologies Ltd 's Suppliers
Subscribers only: Return On Assets for SLGL's Customers

You may also want to know
SLGL's Roi SLGL's Inventory Turnover Ratio SLGL's Growth Rates SLGL's Dividend Comparisons
SLGL's Profitability Ratios SLGL's Asset Turnover Ratio SLGL's Dividend Growth
SLGL's Roe SLGL's Valuation Ratios SLGL's Financial Strength Ratios SLGL's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector ROA
Coherus Oncology inc   42.39 %
Elite Pharmaceuticals Inc   41.21 %
Alpha Tau Medical Ltd  40.35 %
Galmed Pharmaceuticals Ltd   37.04 %
Dariohealth Corp   36.94 %
Abeona Therapeutics Inc   35.76 %
Novavax inc   35.32 %
Medinotec Inc   34.18 %
Zevra Therapeutics Inc   33.84 %
Oramed Pharmaceuticals Inc  33.67 %
Idexx Laboratories Inc  31.91 %
Acadia Pharmaceuticals Inc   29.77 %
Newgenivf Group Limited  29.73 %
Hutchmed china Limited  26.11 %
Petros Pharmaceuticals inc   26.04 %
Adma Biologics Inc   25.98 %
Theravance Biopharma inc   25.35 %
Ptc Therapeutics inc   25.21 %
Qhslab Inc   25.12 %
Rafael Holdings Inc  25.07 %
Medpace Holdings Inc   25.07 %
Mettler toledo International Inc   25.07 %
Compugen Ltd  22.57 %
Lifemd Inc   21.39 %
Catalyst Pharmaceuticals Inc   21.24 %
Iradimed Corporation  20.83 %
Incyte Corporation  20.70 %
Transmedics Group Inc   20.34 %
Eli Lilly And Company  19.76 %
Innoviva Inc   19.19 %

Date modified: 2026-09-18T13:11:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.